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Abstract 
Rhythm control of atrial fibrillation (AF) remains challenging, with modest long 
term success rates. Atrial fibrosis has been associated with AF, but the clinical 
utility of assessment of this fibrosis has yet to be fully elucidated. In this paper 
we review the current state of understanding of the pathophysiology of atrial 
fibrosis in AF, and its impact upon the instigation and propagation of the 
arrhythmia. Fibrosis causes an increase in volume of dysfunctional extracellular 
matrix, and is associated with cellular alterations such as hypertrophy, apoptosis 
and membrane dysfunction within the atrial myocardium. In turn, these cause 
pathological alterations to atrial conduction, such as increased anisotropy, 
conduction block and re-entry, which can lead to AF. We review current methods 
of assessing atrial fibrosis and their impact upon the prediction of success of 
interventional rhythm control strategies such as ablation and cardioversion. We 
focus particularly on circulating biomarkers of fibrosis and scar formation; their 
role in the fibrotic process, and their value in the prediction of rhythm control 
success. We also review imaging and invasive electrocardiographic mapping 
techniques that may identify fibrosis, and again assess their potential predictive 
value. In this area there exist many unanswered questions, but further work will 
help to refine techniques to reliably identify and treat those patients who are 
most likely to benefit from rhythm control treatment strategies. 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 3 
Introduction 
 
Reliable prediction of treatment success for a rhythm control strategy for atrial 
fibrillation (AF) is highly desirable, to minimise unnecessary exposure to 
procedural risk and improve outcomes. Clinical factors favouring rhythm control 
strategies such as ablation include younger age, shorter duration of AF, 
paroxysmal AF, a structurally normal heart, and little comorbidity. Inflammatory 
disorders, valvular disease, left atrial dilatation, cardiomyopathy, and obesity are 
all considered clinical predictors of AF recurrence in individual trials, although a 
meta-analysis found no definitive clinical predictors of recurrent arrhythmia[1]. 
 
Circulating biomarkers may serve as surrogate indicators for advanced atrial 
pathology that may reduce the likelihood achieving rhythm control. If such 
markers could be identified and used in conjunction with clinical and imaging 
criteria, patient selection could be improved, leading to improved success rates 
from rhythm control.  
 
Left atrial fibrosis has been associated with AF, and shown to be a poor 
prognostic marker for maintenance of sinus rhythm. Circulating markers of 
fibrosis may therefore be used as markers of left atrial remodelling. 
 
This review focuses on the pathophysiology of atrial fibrosis, the use of 
serological, electrophysiological, and imaging methods to identify this fibrosis, 
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 4 
and the ability of such methods to predict or improve the success of rhythm 
control treatment of AF. 
 
Selection criteria 
 
We searched Medline (up to November 2015) using the terms “atrial fibrillation” 
and “fibrosis”. The abstracts were screened and full articles relevant to the 
review were selected. In total, 87 articles were selected for inclusion. 
 
The extracellular matrix, collagen turnover, and fibrosis 
 
Cardiac extra-cellular matrix (ECM) consists predominantly of type I (80%) and 
type III collagen and plays an important role in maintaining tissue 
architecture.[2] Furthermore, through interaction with fibroblasts and 
cardiomyocytes, involving TGF-β and angiotensin II paracrine signalling, the 
ECM has an important role in the detection of myocardial stretch.[3] Normal 
ECM is also important for intercellular signalling as well as electrical conduction. 
 
Procollagen is synthesised in the fibroblast endoplasmic reticulum and then 
converted to collagen in the extracellular space by cleavage of the amino and 
carboxyl terminal groups.[4] The ECM is in a constant state of flux.  A number of 
mechanisms regulate collagen turnover (figure 1), and involve transforming 
growth factor β (TGF-β), angiotensin II, platelet-derived growth factor, insulin-
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 5 
like growth factor-1, growth hormone, and endothelins 1 and 3.[3, 5-8] . Matrix 
metalloproteinases (MMPs) are primarily responsible for collagen degradation 
and IL-1, prostaglandin, tumour necrosis factor α (TNF-α), and brain natriuretic 
peptide (BNP) up regulate MMP production.[8-10]  Tissue inhibitors of MMPs 
(TIMPs) are the primary inhibitors of MMPs.  MMPs 1, 2, 7, 8, 9, 10, and 13 have 
major roles in degrading type I and III collagen. 
 
In AF, inflammatory changes in the ECM result in fibrosis.[11]  Left atrial biopsy 
samples in patients with AF  undergoing cardiac surgery have higher levels of  
collagen compared  controls without AF with increased collagen crosslinking. 
[12, 13]  In addition, fibroblast and lymphomononuclear cells proliferate and 
infiltrate atrial tissue. Fibroblasts differentiate into activated myofibroblasts and 
secrete paracrine factors and extracellular membrane proteins.[14, 15] This has 
been shown to cause cardiomyocyte de-differentiation into embryonic precursor 
cells.[16]  Cardiomyocyte structure and function across the atrial myocardium 
become heterogenous, with varying levels of hypertrophy, necrosis, apoptosis 
and proliferation. This heterogeneity, in animal models, provides a substrate for 
AF initiation and perpetuation by interrupting cellular conduction and signalling.  
 
Recent evidence suggests that epicardial adipose tissue may play a major role in 
cardiac inflammation and fibrosis potentially explaining why obesity is a risk 
factor for AF (although it is important to note that epicardial fat does not 
necessarily correlate with BMI).[17] Definitions of epicardial adipose tissue vary 
(many studies include fat in the pericardial space), but the largest such study in 
humans – involving the Framingham cohort – found a strong relationship 
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between pericardial fat (measured by CT) and AF.[18] Other studies have 
associated pericardial/epicardial fat with recurrent AF after ablation.[19, 20] 
Adipose tissue is known to stimulate the production of proinflammatory TNF-α, 
IL-6, TGF-β and MMPs. Thus, a paracrine effect on atrial myocardium, resulting 
in inflammation and fibrosis, has been postulated as a mechanism for the 
generation of AF substrate, as well as the direct effects of adipose infiltration into 
the myocardium.[21] Clinical assessment of these processes could help 
determine left atrial health and may serve as useful prognostic markers. 
Fibrosis as a therapeutic target – is there any benefit? 
Reducing left atrial fibrosis could have important clinical implications.  A number 
of animal studies have shown the adverse effects of left atrial fibrosis. Li et al 
showed that angiotensin II signalling and atrial fibrosis were increased by 
ventricular tachypacing but this could be attenuated with enalapril.[22] In a 
rabbit model of heart failure, inhibition of angiotensin II with pioglitazone and 
candesartan reduced atrial fibrosis, conduction delay and levels of TGF-β1 and 
TNF-α.[23]  Clinical studies have shown similar promise. The TRACE study 
reported a reduction in AF incidence in patients with LV impairment treated 
with trandalopril after myocardial infarction – reduction in angiotensin 
signalling perhaps leading to a reduction in atrial fibrosis.[24]  Furthermore, 
Vermes et al. showed that enalapril could prevent AF in heart failure 
patients.[25] Treatment with irbesartan in addition to amiodarone after 
electrical cardioversion appears to prevent AF recurrence in the absence of heart 
failure.[26] A potential anti-fibrotic role of ACE inhibition was supported in a 
study by Boldt et al. who showed a reduction collagen deposition in ACEI - 
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treated patients .[27] However, in meta analysis and in studies which used AF as 
a pre-determined endpoint, evidence was less convincing - particularly in 
patients without heart failure - that inhibition of the renin – angiotensin system 
prevents AF.[28, 29]  The clinical utility of ACE inhibition for AF remains 
debatable. 
 
Statins may exert anti-inflammatory, anti-oxidant and endothelium – stabilising 
effects that could reduce formation of fibrotic tissue. In animal histological 
experiments, statins have shown beneficial effects on atrial remodelling, and a 
reduction in fibrosis, likely as a result of reduced inflammation.[30, 31] 
Subsequent trials in humans have been mixed, and the largest meta-analysis 
revealed no benefit of statins for primary or secondary prevention of AF. 
Similarly, corticosteroids, which are anti-inflammatory, have not shown clinical 
benefit. 
Predicting the success of treatment with circulating markers 
of fibrosis 
 
There is a dearth of data on the role of circulating markers of fibrosis and 
maintenance of sinus rhythm in patients with AF( table 1). Neither atrial nor 
ventricular fibrosis is specific to AF and a specific of  cardiac fibrosis  has been 
identified. Two studies have attempted to correlate intracardiac marker levels 
with peripheral levels.[32, 33] In these studies, blood was obtained via 
catheterization of the left atrium and coronary sinus, but there were no 
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differences in circulating marker were found. Clinical studies have 
understandably excluded a large number of “real world” patients with AF 
because of confounding comorbidities. Positive associations between circulating 
fibrotic markers and rhythm outcome have only been found in small trials and 
subgroups of larger ones. As a result, odds or hazard ratio confidence interval 
lower limits are often close to 1. So far it seems that only markers of collagen 
types I and III turnover, e.g. PIIINP and CITP have shown promise. Conclusions 
about such biomarkers should be drawn very cautiously, however. As can be 
seen in the studies represented in table 1, the patient populations are 
heterogenous, particularly in terms of the character of AF. Duration, number of 
episodes, and previous treatment of AF are either poorly reported or not at all. 
The conventional AF classification (paroxysmal, persistent, permanent etc.) may 
not be sufficiently discriminative to describe the spectrum of pathology in AF 
patients – thus allowing for significant heterogeneity across study populations. It 
is perhaps unsurprising, therefore, that results frequently conflict.  
Conduction in the fibrotic atrium 
 
The mechanisms by which fibrosis may cause arrhythmia are not yet fully 
described, and are thought to be diverse (Figure 2). 
Extracellular changes 
The architecture of fibrotic myocardial tissue is heterogeneous, and this has a 
variable impact on intercellular conduction.[34, 35] In particular ‘interstitial’ and 
‘patchy’ fibrosis, characterised by the presence of long strands of collagenous 
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material forming insulating septa between bundles of cardiomyocytes 
(perimysial fibrosis) as well as increasing the physical distance between cells 
(endomysial fibrosis).[36] Such extracellular structural alterations appear to be 
progressive and associated with the duration of AF.[37] In a persistent AF goat 
model, this pattern has been shown to increase electrical anisotropy.[38]  
Furthermore, optical mapping of human left atrial appendages in patients with 
AF have corroborates the findings of slower conduction, and structural and 
functional block, which are arrhythmogenic.[39, 40]  
Cellular changes 
Cardiomyocytes change structurally and physiologically,  in effect entering into a 
hibernating state and displaying features usually associated with their 
embryological state.[41] As a result, contractility and excitability are 
reduced.[16] In addition, fibroblasts proliferate and differentiate into 
myofibroblasts.[42] 
 
This is important as fibroblasts have modulating effects on conduction in 
cardiomyocytes, e.g. in response to mechanical stretch.[43].  Studies in rats have 
demonstrated how myofibroblasts can cause slow conduction.[44] The resting 
membrane potential in fibroblasts is less depolarised than cardiomyocytes, 
allowing them to act as a current ‘sink’, increasing the cardiomyocyte refractory 
period.[45] Depolarization of fibroblasts appears to stimulate them to increase 
production of ECM.[45] 
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The presence of these abnormal cell types is associated with abnormal 
conduction. [38, 46-48] For example, conduction velocity appears to be 
decreased by mechanical coupling and paracrine mediation between 
cardiomyocytes and fibroblasts. 53[48] TGF-B1, angiotensin II, VEGF, TNF-A, 
endothelin-1 have been postulated as paracrine mediators.[49] 
 
Normal functional communication between myocardial cells is achieved, in part, 
via gap junctions, expressed by fibroblasts, myofibroblasts, and 
cardiomyocytes.[50, 51]. Gap junctions are identified experimentally by labelling 
of their structural proteins, connexins (Cx). In animals, lower levels of Cx 40 seen 
in AF are thought be a marker of abnormal gap junction function.[52] In human 
AF, connexin expression becomes heterogenous and is increased along lateral 
borders of cardiomyocytes. This finding is supported by electron microscopy, 
and implies abnormal intercellular communication at sites outwith the 
intercalated disc. [36, 53] 
 
Fibrosis and AF are associated with disordered electrotonic coupling, e.g. 
alteration of intracellular calcium concentration in the myofibroblast.[51] Such 
arrhythmogenic ion alterations have been well documented in AF.[54] 
Phenomena such as automaticity and ectopy may occur, at least in part, due to 
this fibrosis - induced disordered electrotonic coupling, as demonstrated in 
computational modelling studies. [55][56, 57] 
 
How, then, do these microscopic mechanisms translate to macroscopic electrical 
changes in the atrium? In a small study (n=6) of bi-atrial mapping in surgical 
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patients with AF, lines of conduction block were noted in the right atrium, 
around which multiple large wavefronts propagated. In the left atrium, multiple, 
high frequency, repetitive activity was documented - lending weight to the 
hypothesis that focal triggers and an arrhythmogenic substrate exist in 
humans.[58] In a sheep heart failure model, fibrosis coincided with enhanced 
endocardial breakthrough in the posterior LA, with intra-mural re-entry 
allowing maintenance of AF.[59] An earlier human study supported the 
heterogenous complexity of wavefronts.[52] Finally, there is significant 
longitudinal dissociation between muscle bundles (with higher levels of 
dissociation in persistent AF cf. acute AF). This results in transient, dynamic 
alterations in wave boundaries, but with fibrillation waves that correspond 
spatially to muscle bundle structure. The predominant feature of persistent AF in 
this study was longitudinal dissociation of conduction with lines of block running 
in parallel with the muscle fibres.  More chaotic fusion and collision of 
wavefronts were seen in acute (induced) AF, suggesting a more organised AF 
substrate in long-standing AF.[60]  
 
The identification of tissue displaying these properties, referred to clinically as 
electrophysiological substrate, has been attractive to clinicians for some time, 
hoping that targeting, or isolating, such areas during ablation procedures may 
increase procedural success. A number of clinical tools have been suggested as a 
means to identify such tissue. e.g. ablation of complex fractionated electrograms, 
however, recent randomised evidence suggests clinical outcomes may not be 
improved by such existing approaches in persistent AF.[61] 
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Identification of fibrosis and targeting of ablation with 
electro-anatomical mapping 
 
The presence of areas of low voltage within the left atrium is independently 
associated with recurrence of atrial arrhythmia after percutaneous ablation, and  
regional structural remodelling (as seen in fibrotic atria) has been associated 
spatially with such low voltage areas.[62, 63] Pulmonary vein isolation remains 
the mainstay of AF ablation, but the identification and ablation or isolation of 
low-voltage areas is a possible therapeutic strategy with encouraging early 
indications in both paroxysmal and non-paroxysmal AF.[64, 65] 
 
Electrophysiological AF substrate is thought, in some instances, to be manifest by 
complex fractionated electrocardiograms (CFAE), although the precise aetiology 
of CFAE is debated, and they are not unique to fibrotic tissue.[66] However, 
attempts have been made to relate CFAEs to atrial fibrosis in humans, after 
evidence that they relate to fibrosis and disordered connexin expression in 
animals.[67] Also, computational modelling suggests that fibroblasts may 
contribute to the presence of CFAE.[68] In the study in humans by Jadidi et al. 
however, CFAE did not relate to areas of fibrosis identified by MRI. Lower 
voltage did relate to these fibrotic areas.[69] In the past, CFAE ablation has been 
a widely - used strategy, but it appears from these results that CFAE does not 
equate sufficiently with substrate, perhaps explaining the limited overall success 
of this approach.[70] Operators must now consider whether targeted CFAE 
ablation can be justified at all, particularly in the light of the STAR-AF II trial 
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which showed no benefit over pulmonary vein isolation alone in persistent AF 
ablation.[61] 
 
Focal impulse and rotor modulation (FIRM) is being explored as a novel method 
to isolate or ablate AF substrate and / or triggers.[71] The phenomena identified 
by FIRM (focal impulses and rotors) have been demonstrated in experimental 
models of AF, although evidence for their role in initiating and maintaining 
human AF is lacking.[72] No clear link with fibrosis has been identified. Recent 
long-term outcome data has been disappointing (in contrast to earlier studies), 
and randomized data is called for.[73] 
 
It is therefore apparent that electrophysiological mapping has its limitations.  
Although identification of low voltage areas has some promise, voltage cut-offs 
for the identification of atrial fibrosis are not established, although a 
classification system has been suggested.[74] Accurate assessment of myocardial 
voltage requires adequate contact between the mapping catheter and the 
myocardium, but high-density mapping catheters with such an ability are 
unavailable. Similarly, the orientation of the catheter, the underlying rhythm, the 
electrode size and the distance between poles all have an impact on accurate 
voltage assessment. The inherent problem of spatial error and drift during a long 
AF case poses a challenge to the idea of targeting areas of fibrosis precisely. EP 
mapping is not suitable to aid the selection of ablation patients.  
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Pre-procedural imaging of fibrosis 
Echocardiography remains the initial method of screening for underlying heart 
disease that may imply lower chances of success – such as left atrial dilatation, 
valvular heart disease, or left ventricular systolic impairment. Magnetic 
resonance imaging (MRI) and computed tomography (CT), have further 
advantages including more accurate analysis of cardiac chamber volume and 
function.[75]. Left atrial fibrosis can be detected by MRI (T1 mapping and 
delayed gadolinium enhancement) or echocardiographic integrated backscatter. 
The latter is not routinely used, but is widely available. It has been associated 
with an increased risk of arrhythmia recurrence after ablation.[76] The 
technique is semi-quantitative, and is subject to the limitations of any 
echocardiographic technique, principally inter-operator variation and the 
variability of image quality between patients. It also lacks the potential to 
provide information regarding the spatial location of fibrotic areas within the 
atrium.  
 
Late gadolinium enhancement (LGE) MRI, on the other hand, can be used to 
quantify overall atrial burden of fibrosis and display it onto a 3-dimensional 
reconstruction. Gadolinium is taken up by cardiac tissue but remains within 
fibrotic tissue for longer than normal tissue. The technique is heavily dependent 
on accurate left atrial segmentation and takes time.  The principal disadvantage 
of MRI, at least at present, hinges around limitations in spatial resolution; the 
smallest resolvable dimension may be similar to the thickness of the atrial wall 
itself, making both qualitative and quantitative assessment of gadolinium uptake 
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challenging. Also MRI is less readily available than echocardiography. 
Nevertheless, a number of studies, most notably the DECAAF study by 
Marrouche et al., have shown significant correlation between fibrosis and 
ablation outcome[77-79]. The group have proposed a classification of LA fibrosis 
from stages I (<10% of the LA wall) to IV (>30%), with recurrence rates of 15% 
and 51%, respectively.  
 
The use of LGE-MRI to guide targeted ablation of discrete areas of fibrosis has 
not yet been studied in depth, although Oakes et al. a showed a quantitative 
relationship between gadolinium enhancement and low voltage areas on EP 
mapping.[80] Improvement in MRI spatial resolution and the combination of 
MRI data with EP data may aid targeted ablation or isolation of AF substrate. 
Conclusion 
Fibrosis is important in the pathophysiology of AF.  A number of methods of 
assessing the extent of fibrosis are available, but have not been validated for 
clinical use. How this data relates to successful restoration of sinus rhythm 
remains unclear. A clinical score to predict outcome based on data from multiple 
sources (e.g. MRI and biomarkers) may be what is needed to help guide 
clinicians as to which patients will maintain sinus rhythm in the long term, 
however, as we have discussed in this review, there are significant conflicts in 
existing data, such that any such scoring system seems a distant prospect. 
Further fundamental research is required, perhaps even redressing the manner 
in which AF is conventionally classified, in order to provide a stable platform for 
future therapeutic directions.  
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Table 1. Studies of  relationship between circulating biomarkers of fibrosis and outcome of cardioversion and percutaneous ablation. 
1st 
Author 
Ref Sample 
Fibrosis marker(s) 
Study pop. Controls 
Follow up 
(months) 
Comments Predictive of 
recurrence 
Not predictive 
Cardioversion 
Kim [81] Plasma TGF-β 
MMP 9 
 
81 - 13 
Multivariate analysis. Length of follow up widely variable. 
TGF-β predicted DCCV failure but not recurrence of AF 
after successful DCCV. 
Kato [82] 
Serum / 
plasma 
MMP 2, TIMP 2 MMP 1, 9 
102 
 
- 28 Pharmacological cardioversion, DCCV if unsuccessful. 
Lombard
i 
[83] 
DNA 
(PCR) 
MMP 1, 3 - 74 - 3 weeks Analysis of gene polymorphism. Short follow up. 
Kawamu
ra 
[84] Serum PIIINP - 
142 
 
- 24 
Pharmacological cardioversion, DCCV if unsuccessful. 
Excluded ACEI/ARB and BB. Short AF duration. 
Mukherj
ee 
[85] Plasma 
MMP 3, 9 
TIMP 4 
MMP 1, 2, 7, 8 
TIMP 1-3 
82 - 
3 
 
Open to type 1 error due to multiple markers. Short follow 
up. 
Kallergis [86] Serum CITP CICP 
164, 
Normal 
 
- 2 
Information on comorbidities not published. Short follow 
up. Population not representative - multiple exclusion 
criteria 
Percutaneous ablation 
Kim [87] Serum - TGF- β,  MMP 1,2,9 242 (mixed PAF and PeAF) - 22 Aimed to show relationship between TGF- β1, TIMP 1, and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 30 
TIMP 1 LA remodelling rather than arrhythmia recurrence. TGF- 
β1 was related to low LA voltage and high LA volume.  
TIMP-1 was related to low LA voltage. 
Okamura [32] 
Serum. 
25 
samples 
from LA 
or mid 
CS 
MMP 2, CITP TIMP 2 
50 
(Mixed PAF/ PeAF/ 
LSPeAF) 
- 14 
AADs stopped at 3 months. MMP 2 predicted recurrence 
irrespective of PAF/non PAF. 
No diff. between LA/CS and peripheral levels. Small 
sample size. 
Richter [88] 
Serum / 
plasma 
PIIINP, but only 
over course of 
follow up 
MMP 9, TGF- β1 
30 
(PAF) 
- 6 
Small sample size. Not aimed at determining predictive 
value of baseline levels, but the changes in levels over 
post-ablation time course. 
Wu [89] Plasma 
TGF- β1 in non-
PAF 
- 200 (mixed PAF/non-PAF) - 6 
TGF- β1 predicted recurrence in the 46 nonPAF patients; 
relatively small sample size for this positive association 
compared to overall number. 95% CI for odds ratio 1.01-
1.22. 
Kimura [90] Serum MMP 2 
CITP, PINP, TIMP 2, 
TGF- β 
44 
(mixed PAF/PeAF) 
- 10 Multiple markers, open to type 1 error. Small sample size. 
Sasaki [91] Serum MMP 2, TIMP 2 TGF- β1 
60 
(mixed PAF/PeAF) 
- 12 
AADs stopped at 2 months. Aimed at post – ablation 
changes in levels. 
Song [92] Serum CTGF in non-PAF - 400 (mixed PAF/non-PAF)  20 AADs stopped at 3 months. Of 400 patients, 92 were non-
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patients PAF in whom the association was found. 95% CI for the 
hazard ratio was 1.074 to 1.436. 
Kornej [33] 
Plasma. 
10 
samples 
from CS 
and LA 
- Gal-3 
105 
(mixed PAF/PeAF) 
14 6 
AADs stopped at ablation. Higher levels of galectin-3 in AF 
patients related to higher BMI on multivariate analysis. 
Canpolat [93] Plasma - 
TGF- β1 (in 
multivariate 
analysis) 
41 (PAF)  18 
AADs stopped after 3 months. TGF- β1 was not 
independently associated with recurrence, but did predict 
extent of fibrosis as assessed by LGE-MRI, which in turn 
predicted AF recurrence. 
Wu [94] Plasma Gal-3 - 50 (PeAF, lone) 46 17 
AADs stopped 2-3 months after ablation. Extensive 
exclusion criteria. Small sample size. 
For abbreviations, see main list. 
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Figures 
 
Figure 1 title – Biomarkers in fibrosis. 
 
Figure 1 legend – green boxes indicate substances measurable in the circulation.  
PICP-procollagen I C peptide, PINP-procollagen I N peptide, PIIICP-procollagen 
III C peptide, PIIINP-procollagen III N peptide, TGF-transforming growth factor, 
PDGF-platelet-derived growth factor, IGF-insulin-like growth factor, GH-growth 
hormone, ET-endothelin, Gal-galectin, CTGF-connective tissue growth factor, IL-
interleukin, BNP-brain-type natriuretic peptide, TNF-tumour necrosis factor, AT-
angiotensin, MMP-matrix metalloprotein, ICTP-collagen I C telopeptide, TIMP-
tissue inhibitor of MMP, CV-conduction velocity 
 
Figure 2 title – Conduction abnormalities in atrial fibrosis 
 
 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 33 
 
 
Fig. 1 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 34 
 
Fig. 2 
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Highlights 
 Fibrosis and atrial fibrillation are associated, although causation remains 
unclear 
 Myocardial changes caused by fibrosis result in diverse conduction 
abnormalities 
 Assessment of fibrosis may aid selection of patients for rhythm control 
 The strengths and weaknesses of these methods are discussed in this 
article 
